NORD Response to the Senate Finance Committee (Minority) Request for Information on Policies for Lowering Drug Prices
Published: Aug 17, 2026
Tagged in: Access to Affordable Medicines
Advancing Rare Disease Research and Regulatory Science
Clinical Trials
Ensuring Adequate Funding for NIH
Federal Drug Pricing Legislation in the 116th Congress
Orphan Drug Act
Out of Pocket Prescription Drug Costs
Rare Disease Clinical Trials
Read full statement >
The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success
Published: Dec 12, 2023
Tagged in: Orphan Drug Act
Read full statement >
Final Inflation Reduction Act Guidance Risks Stifling Innovation for Rare Disease Community
Published: Jun 30, 2023
Tagged in: Advancing Rare Disease Research and Regulatory Science
Medicare, Medicaid, and Private Health Insurance Coverage
Orphan Drug Act
Research
Read full statement >
NORD sends letter with 125 other patient organizations to ask Congressional leadership to reauthorize Title V programs and pass necessary reforms to benefit patients
Published: Nov 14, 2022
Tagged in: Orphan Drug Act
User Fee Act
Read full statement >
NORD and 84 organizations urge Senate HELP leadership to incorporate the RARE Act into the FDA Safety and Landmarks Advancement Act
Published: Jun 3, 2022
Tagged in: Access to Innovative Medicines and Therapies
Advancing Rare Disease Research and Regulatory Science
Orphan Drug Act
Protecting FDA Standards for Safe and Effective Drugs
RARE Act
Read full statement >
NORD drafts comments on Senate Health, Education, Labor and Pensions committee’s discussion on FDA Safety and Landmark Advancements Act
Published: May 22, 2022
Tagged in: Access to Innovative Medicines and Therapies
Expanded Access
FDA’s Accelerated Approval Pathway
Orphan Drug Act
Read full statement >
NORD and 86 other organizations ask for the removal of provisions related to the Orphan Drug Tax Credit in the House version of the Build Back Better Act
Published: Sep 21, 2021
Tagged in: Access to Innovative Medicines and Therapies
Advancing Rare Disease Research and Regulatory Science
Orphan Drug Act
Orphan Drug Tax Credit
Research
Read full statement >
NORD and 86 other organizations oppose the Senate including changes to the Orphan Drug Tax Credit in the Build Back Better Act
Published: Sep 21, 2021
Tagged in: Access to Innovative Medicines and Therapies
Advancing Rare Disease Research and Regulatory Science
Orphan Drug Act
Orphan Drug Tax Credit
Research
Read full statement >
NORD letter to House Ways & Means Committee opposing Section 138141 of the Build Back Better Act
Published: Sep 13, 2021
Tagged in: Access to Innovative Medicines and Therapies
Orphan Drug Act
Orphan Drug Tax Credit
Read full statement >
NORD submits comments on FDA Draft Guidance on Interpreting Sameness for Gene Therapy Products Under the Orphan Drug Regulations
Published: Jul 28, 2020
Tagged in: Access to Innovative Medicines and Therapies
Advancing Rare Disease Research and Regulatory Science
Gene Therapies
Orphan Drug Act
Read full statement >
NORD comments to FDA regarding its definition of low-prevalence in a recent draft guidance
Published: Sep 25, 2018
Tagged in: Access to Affordable Medicines
Access to Innovative Medicines and Therapies
Orphan Drug Act
Read full statement >
NORD comments to the American Medical Association expressing concerns with their resolution proposing reforms to the ODA
Published: Jun 1, 2018
Tagged in: Access to Innovative Medicines and Therapies
Orphan Drug Act
Read full statement >
